The trial, in coordination with Aesculap Biologics, will see Dr. Meininger’s site join RUSH and Mass General among others nationwide with the aim at developing and validating markers for the quality and efficiency of the NOVOCART 3D product, which has been successful in Europe and is trying to obtain a general market authorization in the United States.
The patients will receive one of the therapeutic procedures in the study. The treatment procedure will use a previously specified random process. The probability of the patient being given one of the two treatments is 2:1 with each patient being involved in the study for up to five years.
Read more on sports medicine…
2nd Tommy John surgery linked to pitcher performance decline
PinnacleHealth adds new sports medicine facility
More than than 1/3 of Division I athletes may have low vitamin D
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
